Ankylosing spondylitis - adalimumab, etanercept and infliximab (TA143)
Adalimumab or etanercept are recommended as possible treatments for people with severe ankylosing spondylitis who:
- have active spinal disease as assessed on two separate occasions 12 weeks apart, and
- have tried at least two non-steroidal anti-inflammatory drugs (NSAIDs) but they have not worked.
Healthcare professionals should take into account any disabilities or difficulties in communicating that might mean that the standard assessments do not provide accurate information about a person's spinal disease.
Treatment should be started and supervised by a specialist who is experienced in diagnosing and treating ankylosing spondylitis. People taking adalimumab or etanercept should have regular check-ups. Treatment should continue only if the person's ankylosing spondylitis shows an adequate improvement. If the improvement is not maintained or if the drug stops working then treatment should be stopped.
If a person has to stop taking adalimumab or etanercept during the first 12 weeks of treatment because it has unwanted side effects, their specialist may offer them the other drug as an alternative. However, if treatment with adalimumab or etanercept does not work or stops working, the other drug should not be offered.
Infliximab is not recommended for people with ankylosing spondylitis. Healthcare professionals should not stop prescribing infliximab for people who were already taking it when the guidance was issued. These patients should be able to carry on taking infliximab until they and their healthcare professional decide that it is the right time to stop treatment.
- Ankylosing spondylitis - adalimumab, etanercept and infliximab: review decision - November 2012
- Ankylosing spondylitis - adalimumab, etanercept and infliximab: review proposal - September 2012
- Review decision - May 2011
- Ankylosing spondylitis - adalimumab, etanercept and infliximab: review proposal - November 2010
- NICE issues guidance on treatments for ankylosing spondylitis
This page was last updated: 19 November 2012
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA143 Adalimumab, etanercept ac infliximab ar gyfer spondylitis ymasiol: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
- Audit support
- Costing template
- Biologic drugs for the treatment of inflammatory disease in rheumatology, dermatology and gastroenterology commissioning guide
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.